Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085632 | 0.89 | CES2 (0.47) | CES2CES1FAAH | |
| SCHEMBL4087697 | 0.89 | CES2 (0.47) | CES2CES1FAAH | |
| SCHEMBL4080554 | 0.87 | CES2 (0.48) | CES2CES1FAAH | |
| SCHEMBL28995646 | 0.85 | FAAH (0.47) | CES2CES1FAAH | |
| SCHEMBL2126954 | 0.85 | FAAH (0.47) | CES2CES1FAAH | |
| SCHEMBL9754746 | 0.82 | FAAH (0.48) | CES2CES1FAAH | |
| SCHEMBL25299017 | 0.80 | FAAH (0.50) | CES2CES1FAAH | |
| SCHEMBL2733841 | 0.80 | FAAH (0.50) | CES2CES1FAAH | |
| SCHEMBL17540757 | 0.80 | FAAH (0.50) | CES2CES1FAAH | |
| SCHEMBL2827903 | 0.80 | FAAH (0.50) | CES2CES1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413350-B2 | Long-acting polymeric delivery systems | HERON THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3936115-A1 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS | Heron Therapeutics, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-2831253-B1 | ENZYMES USEFUL FOR PERACID PRODUCTION | DUPONT US HOLDING LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2831250-B1 | ENZYMES USEFUL FOR PERACID PRODUCTION | DUPONT US HOLDING LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2831226-B1 | ENZYMES USEFUL FOR PERACID PRODUCTION | DUPONT US HOLDING LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2831251-B1 | ENZYMES USEFUL FOR PERACID PRODUCTION | DUPONT US HOLDING LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2831252-B1 | ENZYMES USEFUL FOR PERACID PRODUCTION | DUPONT US HOLDING LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11083730-B2 | Long-acting polymeric delivery systems | HERON THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083797-B2 | Long-acting polymeric delivery systems | HERON THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210220474-A1 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS | HERON THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20080176783-A1 | Production of Peracids Using An Enzyme Having Perhydrolysis Activity | DUPONT US HOLDING, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20070184999-A1 | Enzymatic production of peracids using lactobacilli having perhydrolysis activity | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070082832-A1 | Enzymatic production of peracids from carboxylic acid ester substrates using non-heme haloperoxidases | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-04-12 | — | — | US | disclosed |
| EP-0740697-B1 | ENZYMES FOR RECREATIONAL WATER | BUCKMAN LABOR INC (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1224870-A1 | Use of tributyrin in animal feed and corresponding feed additive | Xeris (FR) | 2002-07-24 | — | — | EP | disclosed |
| EP-0740697-A1 | ENZYMES FOR RECREATIONAL WATER | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1996-11-06 | — | — | EP | disclosed |
| US-5507952-A | REDUCING AMOUNT OF ACYLGLYCEROL ESTERS IN WATER BY TREATING WITH MIXTURE OF LIPASE ENZYME, NONIONIC EMULSIFYING AGENT, WATER SOLUBLE UNSATURATED ORGANIC ACID PRESERVATIVE, POLYOL STABILIZER | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5474701-A | Reducing the amount of glycerol esters with a composition comprising a lipase enzyme, a nonionic emulsifier, a preservative and stabilizer | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995020033-A1 | ENZYMES FOR RECREATIONAL WATER | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1995-07-27 | — | — | WO | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413350-B2 | Long-acting polymeric delivery systems | ALOX15, TNNC1, ALOX5 | CES2 307/4885CES1 620/4885HDAC3 2369/4885 |
| US-11083797-B2 | Long-acting polymeric delivery systems | ALOX15, TNNC1, ALOX5 | CES2 307/4885CES1 620/4885HDAC3 2369/4885 |
| US-20210220474-A1 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS | ALOX15, TNNC1, ALOX5 | CES2 307/4885CES1 620/4885HDAC3 2369/4885 |
| US-11083730-B2 | Long-acting polymeric delivery systems | ALOX15, TNNC1, ALOX5 | CES2 307/4885CES1 620/4885HDAC3 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.